【摘要】 应用免疫组织化学方法，研究61例乳腺良、恶性病变c－erbB-2、c－myc的癌基因的表达情况。46例乳腺癌中c－erbB－2和c－myc阳性率分别为50％（23／46）和45．7％（21／46）；15例乳腺良性病变中阳性率分别为6．7％（1／15）和53．5％（8／15）．研究发现，c－erbB-2对乳腺良、恶性病变具有一定的鉴别诊断价值，尤其对浸润性导管癌和髓作癌的诊断更有意义，且有淋巴结转移的乳腺癌中的阳性表达率也明显增高．研究表明c－myc的阳性表达率对乳腺肿瘤无鉴别价值，且发现多种临床病理指标也与c－myc表明无显著关联。更多还原

【Abstract】 Using immunohistochemical method, we examinated the expression of c-erbB-2 and c-myc oncogene in 61 cases of humanbreast benign and melignant diseases. The positive rates of c-erbB-2 and c-myc were 50% (23/46) and 45. 7 % (21 /46) respectively in 46 cases of breast cancer, while those were 6. 7 % (1 /15 ) and 53. 5 %,(8 /15 ) respectively in breast benign diseases. It indicated that c-erbB-2 may be helpful to differential diagnosis of breast benign and malignant diseases. It was particularly useful for diagnosis of invasive ductal breast carcinoma,medullary breast carcinoma and that with axillary lymphnode metastasis. In .addition,it indicated that the c-myc expression was not useful for (lifferential diagnosis of benign and malignant breast diseases and no statistical difference was found between c-myc expression and many clinicopathological factors.更多还原